SOUTH SAN FRANCISCO, Calif.,
May 1, 2020 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today
announced that, due to public health and safety concerns related to
the coronavirus ("COVID-19") pandemic, recommendations and orders
from federal, state and local authorities, and to support the
health and well-being of its stockholders, employees, and others,
it will host its 2020 Annual Meeting of Stockholders ("Annual
Meeting") as a virtual-only meeting that will be held via live
audio webcast. The virtual Annual Meeting is expected to provide
stockholders with the same rights and opportunities to participate
as they would have at an in-person meeting.
The previously announced date and time of the Annual Meeting,
Thursday, May 14, 2020 at
9:00 a.m. Pacific Time, as disclosed
in the previously distributed Notice of the Annual Meeting and
Definitive Proxy Statement (the "Notice and Proxy Statement"), has
not changed. Online access to the Annual Meeting will begin at
8:45 a.m. Pacific Time. Stockholders
will not be able to attend the Annual Meeting in person.
Attending the Virtual Meeting as a Stockholder of
Record
Rigel's stockholders of record as of March 20, 2020 (the "Record Date") can attend the
Annual Meeting by accessing the meeting center
at www.virtualshareholdermeeting.com/RIGL2020 and entering the
16-digit control number on the proxy card or Notice of Internet
Availability of Proxy Materials previously received. The webcast of
the Annual Meeting will be archived for one year after the date of
the Annual Meeting at www.virtualshareholdermeeting.com/RIGL2020.
Instructions on how to connect to the Annual Meeting and
participate via the Internet, including how to demonstrate proof of
stock ownership, are also available at the meeting website.
If you do not have your 16-digit control number, you will be
able to access and listen to the Annual Meeting, but you will not
be able to vote your shares or submit questions during the Annual
Meeting. See caption below titled "Attending the Annual Meeting as
a Guest."
Attending the Virtual Meeting as a Beneficial
Owner
Beneficial stockholders as of the Record Date (i.e.
shares held in "street name" through an intermediary, such as a
bank or broker), who want to attend the Annual Meeting can attend
using the 16-digit control number found on the notice and
instructions received from their broker or other nominee.
Asking Questions
If you are attending the Annual
Meeting as stockholder of record or beneficial owner, questions can
be submitted by accessing the meeting center at
www.virtualshareholdermeeting.com/RIGL2020 and entering your
16-digit control number. Instructions on how to participate in the
Annual Meeting are available on the meeting website.
Voting Shares
Stockholders of record and beneficial
owners will be able to vote their shares electronically during the
Annual Meeting by entering the Annual Meeting using the 16-digit
control number. Instructions on how to vote while participating in
the Annual Meeting live via the Internet are posted at
www.virtualshareholdermeeting.com/RIGL2020.
Rigel encourages stockholders to vote and submit their proxy
in advance of the Annual Meeting by one of the methods described in
the proxy materials for the Annual Meeting.
The proxy
materials, including the proxy card and Notice of Internet
Availability of Proxy Materials, previously distributed along with
the Notice and Proxy Statement, will not be updated to reflect the
change in location and may continue to be used to vote shares in
connection with the Annual Meeting.
Attending the Annual Meeting as a Guest
Guests may
enter the Annual Meeting in "listen-only" mode by entering the
Annual Meeting at www.virtualshareholdermeeting.com/RIGL2020
and entering the information requested in the "Guest Login"
section. Guests will not have the ability to vote or ask questions
during the Annual Meeting.
List of Stockholders
A list of stockholders entitled
to vote at the Annual Meeting will be available for examination for
any purpose germane to the Annual Meeting for ten days prior to the
Annual Meeting. You may email Rigel at ir@rigel.com to
coordinate arrangements to view the stockholder list. The
stockholder list will also be available during the Annual Meeting
at www.virtualshareholdermeeting.com/RIGL2020. Instructions on how
stockholders of records can view the stockholder list during the
Annual Meeting are available on the meeting website.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with immune and
hematologic disorders, cancer and rare diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is
TAVALISSE® (fostamatinib disodium hexahydrate) tablets,
the only oral spleen tyrosine kinase (SYK) inhibitor, for the
treatment of adult patients with chronic immune thrombocytopenia
who have had an insufficient response to a previous treatment. The
product has been approved by the European Commission for the
treatment of chronic immune thrombocytopenia in adult patients who
are refractory to other treatments, and will be marketed in
Europe under the name TAVLESSE™
(fostamatinib).
Rigel's clinical programs include a Phase 3 study of
fostamatinib in warm autoimmune hemolytic anemia (AIHA); a
completed Phase 1 study of R8351, a proprietary molecule
from its interleukin receptor associated kinase (IRAK) inhibitor
program; and an ongoing Phase 1 study of R5521, a
proprietary molecule from its receptor-interacting protein kinase
(RIP) inhibitor program. In addition, Rigel has product candidates
in clinical development with partners Aclaris Therapeutics,
AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
IR Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/rigel-announces-change-to-virtual-format-for-2020-annual-meeting-of-stockholders-301050778.html
SOURCE Rigel Pharmaceuticals, Inc.